Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Copenhagen uPAR prostate cancer (CuPCa) database: protocol and early results

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. ProANP and proBNP in plasma as biomarkers of heart failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Commentary: Measurement of biomarkers in medicine

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  3. Copeptin levels and invasive hemodynamics in patients with advanced heart failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Chemerin is elevated in multiple myeloma patients and is expressed by stromal cells and pre-adipocytes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Fetal cells in maternal blood for prenatal diagnosis: A love story rekindled

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Systemic Immune Modulation in Gliomas: Prognostic Value of Plasma IL-6, YKL-40, and Genetic Variation in YKL-40

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Gel-Based Proteomics of Clinical Samples Identifies Potential Serological Biomarkers for Early Detection of Colorectal Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

AIM: Urokinase plasminogen activator receptor (uPAR) plays a central role during cancer invasion by facilitating pericellular proteolysis. We initiated the prospective 'Copenhagen uPAR Prostate Cancer' study to investigate the significance of uPAR levels in prostate cancer (PCa) patients.

METHODS: Plasma samples and clinical data from patients with newly diagnosed PCa have been collected prospectively. The uPAR forms have been measured in plasma using time-resolved fluorescence immunoassays.

RESULTS: The level of intact uPAR(I-III) did not differ. Plasma uPAR(I-III) + uPAR(II-III) levels and uPAR(I) levels were significantly higher in hormone-naive and castrate-resistant patients compared with patients with localized disease (both: p < 0.0001).

CONCLUSION: Our results show that cleaved uPAR forms are significantly increased in patients with advanced PCa.

OriginalsprogEngelsk
TidsskriftBiomarkers in Medicine
Vol/bind10
Udgave nummer2
Sider (fra-til)209-16
Antal sider8
ISSN1752-0363
DOI
StatusUdgivet - feb. 2016

ID: 46218048